Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

(2012) Lot A. Devriese et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

(2012) L. A. Devriese et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

(2012) L. A. Devriese et al.   INVESTIGATIONAL NEW DRUGS

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

(2012) J. G. Coen van Hasselt et al.   PHARMACEUTICAL RESEARCH

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

(2011) J. S. de Bono et al.   ANNALS OF ONCOLOGY

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

(2011) K. Aogi et al.   ANNALS OF ONCOLOGY

A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer

(2011) Alexander I. Spira et al.   Clinical Lung Cancer

Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity

(2011) J G C van Hasselt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Eribulin mesylate in patients with refractory cancers: a Phase I study

(2011) Toru Mukohara et al.   INVESTIGATIONAL NEW DRUGS

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

(2010) Ron J. Keizer et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

(2010) Elena Soto et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model

(2009) Lena E. Friberg et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

(2009) Anthe S. Zandvliet et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS